- Home
- GAM vs SVRA Comparison
GAM vs SVRA Comparison
Compare GAM & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GAM | SVRA |
|---|---|---|
| Founded | 1927 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | N/A | 2009 |
Fundamental Metrics
Financial Performance| Metric | GAM | SVRA |
|---|---|---|
| Price | $64.25 | $5.52 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $7.33 |
| AVG Volume (30 Days) | 28.1K | ★ 2.0M |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | ★ 5.74% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 11.67 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $430.87 |
| P/E Ratio | $5.55 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $56.24 | $2.26 |
| 52 Week High | $66.18 | $7.01 |
Technical Indicators
Market Signals| Indicator | GAM | SVRA |
|---|---|---|
| Relative Strength Index (RSI) | 52.33 | 42.96 |
| Support Level | $62.27 | $5.47 |
| Resistance Level | $64.60 | $6.15 |
| Average True Range (ATR) | 0.66 | 0.26 |
| MACD | 0.06 | -0.10 |
| Stochastic Oscillator | 68.53 | 11.11 |
Price Performance
Historical ComparisonAbout GAM General American Investors Inc.
General American Investors Co Inc is a closed-end, diversified management investment company. The primary investment objective of the company is long-term capital appreciation through investment in companies with above-average growth potential. It focuses on equity securities with growth potential at reasonable valuations. The company invests principally in common stocks believed by management to have growth potential.
About SVRA Savara Inc.
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).